key: cord-0783908-gnxgpvnz
authors: Nath, Virendra; Rohini, A.; Kumar, Vipin
title: Identification of M(pro) Inhibitors of SARS-CoV-2 Using Structure Based Computational Drug Repurposing
date: 2021-10-01
journal: Biocatal Agric Biotechnol
DOI: 10.1016/j.bcab.2021.102178
sha: 5e3f36e821d1361170ba83e7d8974e09e9162bed
doc_id: 783908
cord_uid: gnxgpvnz

The recent outbreak of COVID-19, caused by the novel pathogen SARS-coronavirus 2 (SARS-CoV-2) is a severe health emergency. In this pandemic, drug repurposing seems to be the most promising alternative to identify effective therapeutic agents for immediate treatment of infected patients. The present study aimed to evaluate all the drugs present in drug bank as potential novel SARS-CoV-2 inhibitors, using computational drug repurposing studies. Docking-based virtual screening and binding energy prediction were performed, followed by Absorption Distribution Metabolism Excretion calculation. Hydroxychloroquine and Nelfinavir have been identified as the best potential inhibitor against the SARS-CoV-2, therefore, they were used as reference compounds in computational DR studies. The docking study revealed 13 best compounds based on their highest binding affinity, binding energy, and dock score concerning the other screened compounds. Out of 13, only 4 compounds were further shortlisted based on their binding energy and best ADME properties. The hierarchical virtual screening yielded the best 04 drugs, DB07042 (compound 2), DB13035 (compound 3), DB13604 (compound 5) and DB08253 (compound 6), with commendable binding energies in kcal/mol, i.e. -65.45, -62.01, -52.09 and -51.70 respectively. Further, Molecular dynamics simulation with 04 best-retrieved hits has confirmed stable trajectories in protein in terms of root mean square deviation and root mean square fluctuation. During 30 nanosecond simulation, the interactions were also found similar to the docking-based studies. However, clinical studies are necessary to investigate their therapeutic use against this outbreak.

. However, the measures that have been 111 implemented remain limited to preventive and supportive therapies. Common symptoms of a 112 person infected with coronavirus include respiratory symptoms, fever, cough, shortness of 113 breath, and dyspnea. In more severe cases, the infection can cause pneumonia, severe acute 114 respiratory syndrome, kidney failure, and even death (Catharine I. Paules, HilaryD. Marston, 115 2020). 116 In this pandemic situation where novel therapeutics is required immediately, the most 117 efficient way to investigate the treatment options seems to be the re-purposing of therapeutic 118 drugs. Several drugs have already been tested, among which hydroxychloroquine and 119 Nelfinavir, are among the promising drugs which have shown efficacy in the treatment of 120 COVID-19 associated respiratory problems in recent clinical studies (Baildya, Ghosh, & 121 Chattopadhyay, 2020; Colson, Rolain, Lagier, Brouqui, & Raoult, 2020; Gautret et al., 2020; 122 Musarrat et al., 2020; Nicola Principi, 2020; Sahraei, Shabani, Shokouhi, & Saffaei, 2020; 123 Shah, Das, Jain, Misra, & Negi, 2020; Z. Yamamoto et al., 2004; Colson et 124 al., 2020; Z. Xu et al., 2020) . 125 In the present study, drug repurposing using in silico studies has been used, in which all drugs 126 of drug bank were subjected to the ensemble docking campaign and binding energy 127 prediction to identify hit candidate that could bind at the active site of SARS-CoV-2 protein 128 (6LU7) and may cause inhibition of SARS- CoV-2 (Amaro et al., 2018; Van Norman, 2016; 129 Choudhary & Silakari, 2020). Further, the present studies were able to identify thirteen top-130 ranked compounds, which are currently available and have had either regulatory approval as 131 drugs or had multiple prior studies that indicate high potential for therapeutic use. Out of the 132 13 drugs selected, based on their binding affinity and interactions with SARS-CoV-2, 04 best 133 drug hits were shortlisted that were also compared with currently available standard drugs 134 against COVID-19 i.e. Hydroxychloroquine and Nelfinavir. These four drugs have a similar 135 type of protein-ligand interaction in the binding pocket of SARS-CoV-2 (6LU7) protein as 136 standard drugs (Hydroxychloroquine and Nelfinavir) and thus, could serve as appropriate 137 candidates for immediate experimental studies. The X-Ray crystal structure of SARS-CoV-2 which causes COVID-19 was chosen from 140 protein databank (PDB ID 6LU7) as docking template because it was found to have good 141 resolution of 2.1 Å (Jin et al., 2020a (Jin et al., , 2020b . The protein preparation wizard was used to 142 correct the addition of hydrogens, disulfide bonds establishment, assigning bond orders, and 143 deletion of water molecules beyond 5Å. Further, steric hindrances in the target site were 144 removed by optimizing and minimizing the hydrogen bonds. Moreover, the missing side 145 chains and loops were used for filling through the Prime module (Roos et al., 2019; 146 Genheden & Ryde, 2015) . Docking studies were performed on a prepared X-Ray crystal 147 structure of SARS-CoV-2 which was chosen from protein data bank (PDB ID 6LU7).

3D grid was generated at the N3 site which is a Michael acceptor inhibitor having 150 (cytotoxicity concentration) CC50 >133 μM and the substrate-binding site is situated between 151 domain I and II as reported in previous works of literature (Jin et al., 2020a (Jin et al., , 2020b . The 152 generation of the 3D grid was further done by using SiteMap analysis, which provides 153 information about the size, hydrophilic and hydrophobic areas of the binding site. Hydrogen 154 bond acceptors, as well as donor areas on ligand or receptor, are also evaluated by SiteMap 155 analysis (Halgren, 2007 

Many of the drugs are rejected due to their abnormal pharmacokinetic features that may 193 include alarming absorption, distribution, metabolism, or excretion (ADME) parameters.

Therefore, the pharmacokinetic features of the best-obtained candidates were assessed using 195 the QikProp module version5.9 by conforming to the rule of five and three to evaluate some 196 vital properties such as blood-brain barrier permeability, polar surface area, human oral 197 absorption percentage, and molecular weight (Chatterjee, Cutler, Doerksen, Khan, & 198 Williamson, 2014; Dzierba et al., 2007) . 

The grid at the N3 site of 6LU7 was successfully generated which was further validated by Table 2 . Therefore, may also be helpful in Percentage of human oral absorption was also good and scaled from 45% to 90%. The 280 predicted gut blood barrier which is non-active transport and these four hit drugs seems in the 281 admissible range i.e. 25nm/sec. to 500nm/sec. These hit drug candidates were reported as 282 experimental or investigational drugs in the drugbank database and may help against the 283 novel CORONA virus. DB13604, which is also a lead compound and known as AG-24322; 284 an investigational drug that was tested against the cancer cells as a cell cycle inhibitor 285 whereas, all other three hit drugs were in the experimental category and their 286 pharmacological action was unrevealed in the database. 

QPPCaco: Caco-2 cell permeability in nm/s. Caco-2 cells are a model for the gut-blood barrier (<25 poor, >500 304 great).

logBB: Predicted brain/blood partition coefficient (-3.0-1.2).

Percent human oral absorption predicted human oral absorption on 0-100% scale (>80% high, <25% poor).

MDCK predicted apparent MDCK cell permeability in nm/sc. MDCK cells are considered to be a good mimic 308 for the blood-brain barrier <25 poor, >500 great The trajectory analysis revealed the RMSD plot which was found stable throughout the 317 simulation with all hits. RMSD and RMSF were recorded differently in individual P-L 318 complexes which were found below 2.4Å and approximately 2.0Å respectively for all 04 hits.

The results of MD simulations are shown comprehensively in Table 4 and Figure 9 to 11. 320 Table 4 . Comprehensive MD simulation results of complex of retrieved hits with 6LU7. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Discovery of 414 thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors 415 by structure-based virtual screening

Scaffold morphing of arbidol (umifenovir) in search of 418 multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other 419 proteases involved in COVID-19

Chloroquine and 422 hydroxychloroquine as available weapons to fight COVID-19

Antimicrobial Agents 105932

Dihydropyridopyrazinones and dihydropteridinones as 428 corticotropin-releasing factor-1 receptor antagonists: Structure-activity relationships and 429 computational modeling

Comprehensive virtual screening of the antiviral 433 potentialities of marine polycyclic guanidine alkaloids against sars

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-439 label non-randomized clinical trial

The MM / PBSA and MM / GBSA methods to estimate 442 ligand-binding affinities

Three Emerging Coronaviruses in Two Decades: The Story of SARS

New method for fast and accurate binding-site identification and analysis

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor 451 ACE2 and the cellular protease TMPRSS2 for entry into target cells

VDM: visual molecular dynamics

Molecular dynamics analysis of phytochemicals from Ageratina 499 adenophora against COVID-19 main protease (Mpro) and human angiotensin-converting 500 enzyme 2 (ACE2)

Chloroquine or hydroxychloroquine for 503 prophylaxis of COVID-19

A model of the ACE2 structure and function 505 as a SARS-CoV receptor

Extending Force Field Coverage for Drug-Like Small Molecules

Aminoquinolines against 512 coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

A systematic review of the 516 prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 517 (COVID-19)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval 520 Processes for Drugs

Evolution of 523 the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike 524 protein for risk of human transmission

Nelfinavir was 527 predicted to be a potential inhibitor of 2019-nCov main protease by an integrative 528 approach combining homology modelling, molecular docking and binding free energy 529 calculation

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated 534 coronavirus

Cys160(53%)

Ser158(60%), Gln110(80%), Phe294(50%), Asp248(50%)

Asp153(10%)

Asp153(79%), Tyr154(65%), Phe294(38%), Thr111(40%)

Gln110(10%)

Ser158(10%)

Gln288(>100%)

Asp289(98%)

Tyr126(2%)

Gln288(>100%), Gln290(>100%), Gln127(60%), Lys5(99%)

Lys137(21%)